Unexplained Abuses of Human IgG Subclass Denomination in Antibody Patents Jérémy PottierHervé Watier Commentary 23 April 2014 Pages: 327 - 329
Multi-Specific Antibodies for Cancer Immunotherapy Ron D. JachimowiczSven BorchmannAchim Rothe Leading Article 18 March 2014 Pages: 331 - 343
siRNA Technology in Kidney Transplantation: Current Status and Future Potential Kristina GlebovaOleg N. ReznikMikhail Skoblov Review Article 27 February 2014 Pages: 345 - 361
Drift, Evolution, and Divergence in Biologics and Biosimilars Manufacturing Sundar RamananGustavo Grampp Review Article 25 February 2014 Pages: 363 - 372
Targeting the PI3K/Akt/mTOR Pathway in Malignancy: Rationale and Clinical Outlook Daniel C. Cho Review Article 25 February 2014 Pages: 373 - 381
Practical Considerations for the Pharmacokinetic and Immunogenic Assessment of Antibody–Drug Conjugates Melody SauerbornWilliam van Dongen Review Article 20 May 2014 Pages: 383 - 391
Purification, Characterization and Plasma Half-Life of PEGylated Soluble Recombinant Non-HA-Binding CD44 Anne PinkAili KallastuAndres Valkna Original Research Article 25 February 2014 Pages: 393 - 402
Ranibizumab: A Review of its Use in Myopic Choroidal Neovascularization Emma D. Deeks Adis Drug Evaluation 28 June 2014 Pages: 403 - 410
Human Immunoglobulin 10 % with Recombinant Human Hyaluronidase: Replacement Therapy in Patients with Primary Immunodeficiency Disorders Mark Sanford Adis Drug Evaluation 13 June 2014 Pages: 411 - 420
